Cytel and Pulse Infoframe Collaborate on Real-World Data Solutions to Address Rare Disease Research
December 9, 2021
Cytel and Pulse Infoframe said they have entered into a partnership to support drug development sponsors seeking to implement real-world evidence solutions for a range of purposes, from synthetic controls and comparative effectiveness to pricing reimbursement.
Cytel, an advanced analytics provider for life sciences decision makers, has developed new methods to ensure data reveals its full value. It has had regulatory success obtaining approval by leveraging real-world data as a synthetic control arm. The new collaboration builds on Cytel’s expertise in clinical trial design and real-world data solutions.
Pulse Infoframe’s healthie platform simplifies the workflow for data capture, integration and management, while ensuring that all the data captured is mapped according to global standards such as OMOP and CDISC.
Both companies will combine their expertise to channel real-world evidence toward new treatments in rare disease. Because rare disease research and drug development have historically been confronted with limited sample sizes, they have required innovative approaches to clinical development and evidence generation. The use of real-world data to support regulatory and payer submissions is therefore essential to ensure that stakeholders review the most comprehensive evidence package, enabling faster access to new treatments in areas of high, unmet need.
“Rare disease patients can wait years for even the smallest advancement in treatment,” Femida Gwadry-Sridhar, the CEO and founder of Pulse Infoframe said. “In many cases, those advancements may not come at all. By collaborating with Cytel, a company renowned for their quantitative methods for improved research outcomes and exemplary trial design, we can help accelerate drug development for rare diseases.”
Author: Rare Daily Staff
Sign up for updates straight to your inbox.